Skip to content

Comparison of the Effectiveness of Therapeutic Ultrasound and Phonophoresis in Chronic Low Back Pain

Comparison of the Effectiveness of Therapeutic Ultrasound and Phonophoresis Applications in Patients With Chronic Low Back Pain

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06959394
Enrollment
60
Registered
2025-05-06
Start date
2025-09-01
Completion date
2025-12-30
Last updated
2026-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Back Pain

Brief summary

The aim of this study is to evaluate the effects of therapeutic ultrasound and phonophoresis applications on pain, range of motion, flexibility and functional capacity in patients with chronic low back pain. The study is planned as the first scientific study comparing the effectiveness of these two physiotherapy methods in the treatment of chronic low back pain. It is aimed to make national and international publications with the data obtained at the end of the study. The study will be conducted in a randomised single-blind, placebo-controlled design. 60 patients aged 18-30 years with chronic low back pain will be divided into 3 groups: therapeutic ultrasound (US) application, phonophoresis application and placebo US group. In addition to ultrasound and phonophoresis, TENS, infrared and low back exercises will be applied to all groups as treatment. Pain intensity (VAS), functional status (Oswestry disability index), flexibility (Sit-to-Sit test) and range of motion (goniometric measurements) will be assessed throughout the treatment period. The study aims to make an important contribution from a clinical and economic point of view, given the increasing prevalence of low back pain worldwide and the need for treatment. The findings may guide the development of future treatment modalities.

Interventions

OTHERUltrasound

Participants will receive ultrasound at 1.5 W/cm2 for 6 minutes (transmitter agent aquasonic gel) 5 sessions per week for 2 weeks.

Participants will receive ultrasound with 1.5 W/cm2, 6 min (transmitter diclofenac gel) for 5 sessions per week for 2 weeks.

OTHERPlacebo

Participants will receive 0 W/cm2, 6 min ultrasound, 5 sessions per week for 2 weeks.

Sponsors

KTO Karatay University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

Individuals with low back pain for more than 3 months and pain intensity more than 5 according to VAS will be included in the study

Exclusion criteria

patients who have undergone surgical operations

Design outcomes

Primary

MeasureTime frameDescription
pain severityBaseline and after 2 weeks intervationVisual Analog Scale

Secondary

MeasureTime frameDescription
functional stateBaseline and after 2 weeks intervationOswestry Disability Index
FlexibilityBaseline and after 2 weeks intervationSit and Reach Test
range of motion of the jointBaseline and after 2 weeks intervationGoniometry

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026